Aptevo Therapeutics reports Q3 EPS ($2.23) vs. ($357.86) last year

“We continue to make disciplined progress across both our clinical and research programs,” said Marvin White, President and Chief Executive Officer of Aptevo. “The Cohort 3 results reinforce mipletamig’s potential to meaningfully improve outcomes for patients with frontline AML – a population that has had very limited treatment options. At the same time, the introduction of trispecific candidates, APVO451 and APVO452, reflects the continued strength of our platform strategy and our commitment to thoughtfully expanding the pipeline where we believe we can have real impact. Our approach remains focused, data-driven, and rooted in the belief that well-designed immunotherapies can be both powerful and tolerable for patients.”